Financial information

Facts and figures, shareholder's guide & press releases

Events & financial agenda

Sales figures, results announcements and assembly dates.

26 September 2022
Half year results 2022
31 March 2022
Annual results 2021
31 January 2022
Annual sales 2021
23 September 2021
Half year results 2021
12 July 2021
Half year sales 2021
22 June 2021
Annual Shareholders meeting 2021
22 March 2021
Annual financial results 2020
19 January 2021
Annual sales 2020
Shareholders' guide

Listed on Alternext Paris
Eligible PEA PME
Initial listing: 25 April 2014
Number of shares: 15 247 329
ICB Classification (Sector):
4535 Medical Equipment

Identification codes:
Name: THERACLION
ISIN: FR0010120402
LEI: 9695007X7HA7A1GYD29
Ticker: ALTHE
Bloomberg: ALTHE.FP
Reuters: ALTHE.FA

Annual Closure: 31 December

Liquidity contract:
CM-CIC Market Solutions

Analyst coverage:
Farny Meindre CM-CIC Market Solutions
Thibault Voglimacci-Stephanopoli Invest

 

 

Shareholders
Press releases

Newsworthy statements, milestones and announcements.

30 January 2023
Theraclion announces results of first US trial
16 January 2023
Theraclion reaches major milestones in 2022, paving the way for the commercial deployment of SONOVEIN®
21 December 2022
University of Virginia (UVA) cancer center to use Theraclion’s HD technology
14 November 2022
Theraclion successfully represented at the 8th international symposium on focused ultrasound
17 October 2022
Last patient of first SONOVEIN® US study has been treated
29 September 2022
New echotherapy for varicose veins partnership with Parisian region hospital wound center announced
26 September 2022
The new strategy is paying off
27 July 2022
A harvest of good news
21 June 2022
95% vein occlusion rate: results presented by Dr Stalnikiewicz at Swiss Vein Days 2022
13 June 2022
HIFU and their use in immune-oncology presented at the annual scientific meeting of the society of interventional radiology in Boston
16 May 2022
Theraclion launches SONOVEIN® HD, its new robotic platform for veins
11 May 2022
First patients treated with Theraclion’s SONOVEIN®in the US
20 April 2022
Theraclion announces 1,000th treatment for varicose veins with SONOVEIN ®
31 March 2022
2021 results in line with Theraclion’s development strategy for 2022
8 March 2022
Theraclion announces first patient inclusion in early-stage breast cancer study
25 February 2022
Theraclion announces the successful completion of a €6.5 million capital increase
31 January 2022
Theraclion ready to scale up in 2022
24 January 2022
Yann Duchesne appointed new executive chairman to lead major shift in Theraclion’s strategy
13 December 2021
Theraclion’s is deploying its scalable robotic platform SONOVEIN® in Europe
22 November 2021
Theraclion’s first varicose veins treatment in Hong-Kong opens perspectives in Asia
23 September 2021
Theraclion results show strong recovery, allowing ambitious plans
21 September 2021
FDA approves the 1st trial with Theraclion’s vein therapy in the US
12 July 2021
Theraclion’s sales multiplied by 5 in the first half of 2021
22 June 2021
Theraclion strengthens its Board of Directors
9 June 2021
Bernard Sabrier and Unigestion pass the 20% threshold, proof of confidence in the company’s development
1 June 2021
UVA Cancer Center to expand use of Theraclion’s HIFU system in cancer treatment research.
22 March 2021
In 2020, Theraclion has succeeded a crucial step for its technology.
19 January 2021
Theraclion’s strategy is in place for 2021 despite the impact of Covid-19 on sales revenues for 2020
17 December 2020
Renewed investor confidence in Theraclion
21 October 2020
Positive and differentiated results for Theraclion’s non-invasive varicose vein treatment technology revealed at the 34th AVLS
15 October 2020
Theraclion’s 2nd generation breakthrough technology for varicose vein treatments ready to launch
28 April 2020
Christopher S. Bödtker appointed Chairman of Theraclion
30 January 2020
Clarification on its cash flow situation
17 October 2019
Truffle Capital shareholding reduced to 2.4%
22 July 2019
Revenue H1 2019
15 May 2019
Four Systems Sales and Major Reimbursement Agreement
16 April 2019
CE mark for the non-invasive treatment of varicose veins
12 February 2019
€11.8 million new financing package concluded
2 February 2019
Revenu 2018
24 October 2018
Tübingen/Fus
2 October 2018
Progress in Switzerland and Germany
1 October 2018
First European podium presentation of SONOVEIN
24 September 2018
First Half 2018 Results
28 August 2018
Theraclion achieves key milstones in Germany
27 June 2018
First patient in Forfait Innovation
15 June 2018
First Echotherapy Center in Berlin
7 June 2018
Theraclion completes first varicose veins study
7 June 2018
Theraclion completes first varicose veins study
11 April 2018
Sales and clinical development in Asia
26 February 2018
First Echopulse® in Catalonia, Spain
8 February 2018
Theraclion Accelerates its Growth in 2017
8 January 2018
Immunotherapy breast cancer strategy
21 December 2017
First patient treatments in Poland
21 December 2017
First sale to Poland
18 December 2017
First 5 Theraclion Echopulse systems delivered to China
18 December 2017
First sales to China
13 December 2017
Reimbursement to 15 Million covered German lives
11 December 2017
Two sales to Eastern Europe and China
20 November 2017
New clinical data to be presented during RSNA
15 November 2017
Preliminary Results In the Treatment of Varicose Veins
6 November 2017
Webinar to discuss preliminary results in veins
31 October 2017
Information on shareholding
26 October 2017
Theraclion makes substantial progress towards market access
17 October 2017
Theraclion raises € 4.2 million
16 October 2017
Study in non-invasive varicose vein treatment and the launch of a capital increase
9 October 2017
Exclusive Distribution Agreement with EDAP TMS France
27 September 2017
Theraclion Extends Market Access and Regulatory Approval
25 September 2017
Key markets Germany and Hong Kong, China
11 September 2017
f First Clinical Trial Combining Echotherapy and Imunotherapy to Treat Metastatic Breast Cancer
29 August 2017
Promising clinical trial results in a new thyroid indication
9 August 2017
Conference Call on First Immuno-Oncology Metastatic Breast Cancer Trial
6 August 2017
New clinical study results (Tübingen)
19 July 2017
Theraclion Announces Expansion of Echotherapy Reimbursement Coverage to 14 Million Lives in Germany
3 July 2017
World’s largest & first Asian study
23 May 2017
Improved Outcomes Compared to Surgical
15 May 2017
First oncological veterinary patient
2 May 2017
Presentation of U.S. clinical data
24 April 2017
Joint Venture in China
6 April 2017
Long-term Echopulse® results in breast fibroadenoma
28 February 2017
2017 German Stevie Awards
8 February 2017
U.S. pivotal multicentre FDA Study
15 December 2016
French authorities grant derogation reimbursement
28 November 2016
Sales UK
26 September 2016
New Clinical Data Strongly Support the Safety and Efficacy
7 September 2016
18th Annual Rodman & Renshaw Global Investment Conference
6 September 2016
Major German Insurance Company in AOK
31 August 2016
First Data Generated in U.S.
20 July 2016
First acquisition of Echopulse® in Switzerland
29 June 2016
First agreement in Italy
24 June 2016
HAS first positive feedback to Forfait Innovation
14 June 2016
Sales in Hamburg
8 June 2016
New clinical study results
8 June 2016
De nouveaux résultats d’études cliniques
24 May 2016
+115% growth in treatment numbers
2 May 2016
Large Chinese Biotech & Pharmaceutical group acquires 8%
4 April 2016
Sales to German Nuclear Medicine Practice
21 March 2016
Extended reimbursement in Germany
10 March 2016
Treatment number growth
8 February 2016
First Patients in the UK
3 February 2016
Theraclion’s growth continues in 2016
26 January 2016
Submission for « Forfait Innovation »
11 January 2016
Annual Results 2015
18 November 2015
BEAMOTION marquée CE
31 August 2015
First European commercial agreements in Thyroid
15 July 2015
Start of clinical trials
2 July 2015
First reference site in Asia:
29 June 2015
Theraclion’s managers and employees invest in capital equity
11 June 2015
First Sales in Egypt
9 June 2015
Theraclion receives an additional financing
27 April 2015
German Patients Covered
15 April 2015
Business Development Director for Asia
18 March 2015
Signature of Equity Line
18 March 2015
Further reimbursements in Germany
16 March 2015
Publication on Thyroid
12 March 2015
Asia & Nominations
12 February 2015
Publication in JTU
13 January 2015
Sales Agreement and First International Publication
15 December 2014
Nomination and Sales
24 November 2014
Nomination of a VP Business Development
9 November 2014
First reimbursements in Germany
2 November 2014
Strengthening management team
15 October 2014
Publication in Intl J of Hyperthermia
2 October 2014
Publication in J. of Therap. Ultrasound
23 July 2014
Theraclion receives €900 thousand from Bpifrance’s “Industrial Strategic Innovation” program
3 April 2014
Theraclion obtains FDA approval for IDE
3 April 2014
FDA approval for IDE in USA for Breast Fibroadenoma
12 December 2012
CE Mark breast fibroadenoma
12 December 2012
CE marking approval for Breast Fibroadenoma
29 November 2011
First successfully treated breast fibroadenomas in two patients
29 November 2011
First succesful treatments of patients for Breast fibroadenoma
18 November 2009
Frost & Sullivan European Ultrasound Technology Innovation Award
18 November 2009
Theraclion receives the Frost & Sullivan European Ultrasound Technology Innovation Award
Financial reports & presentations

Key economic and financial information
(click here for more reports) 

2020 2019 2018 2016 2015 2014
Results
Other regulatory documentation

Products Instructions For Use (English)

  • SONOVEIN ref. THC903359-B
  • EPack ref. THC903400-A

Password protected – refer to your training materials.

Contact us

Move to what moves you - for profit AND for people.
Get in touch